Guggenheim Maintains Buy on Rapport Therapeutics, Raises Price Target to $70

Benzinga · 2d ago
Guggenheim analyst Delma Caiati maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $65 to $70.